Skip to main content
OpenTrials
Completed

NCT Number: NCT00146445

Behavioral Intervention Trial for HIV-infected Injection Drug Users

The purpose of this study is to test whether a ten-session behavioral intervention for HIV-infected injection drug users is effective in reducing sex and injection risk behaviors that put others at risk for HIV infection, increasing access to or utilization of HIV primary health care, and increasing adherence to HIV medications.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

HIV

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

University of California - San Francisco, San Francisco, California, United States

Loading trial locations.

About this study

INSPIRE is a four-site (Baltimore, Miami, New York and San Francisco) randomized control trial to develop and evaluate the efficacy of a ten-session intervention for HIV-positive injection drug users. The primary goals of the intervention are to:

  • decrease sex and injection risk behaviors that put others at risk for HIV infection,
  • increase access to or utilization of HIV primary health care, and
  • increase adherence to HIV medications.

The intervention arm consists of 7 group sessions, 2 individual sessions, and one community experience. The control arm consists of 8 group sessions, aiming at controlling for demand (1st session) and attention (8 group sessions). Behavioral assessments and blood draws (for viral load and CD4 testing) occur at baseline, 6, and 12 month follow-up; a 3 month assessment involves behavioral assessment only. 1161 participants took baseline. Of these, 966 were randomized into the study, and 840, 807, and 821 participants took 3, 6, and 12 month follow-up assessments, respectively.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years of age or older
  • self-identify as a person who has injected drugs in the last 12 months
  • self-identify as a person who has had sex with at least one opposite sex partner within the last 3 months
  • self-identify as HIV-seropositive
  • be confirmed as HIV seropositive through oral fluid (saliva) HIV testing
  • live in the geographic region under study,
  • agree to have their blood drawn for CD4 count and viral load testing
  • be willing to provide basic contact information (for follow-up)
  • be able to communicate in English
  • not have participated in the full-pilot of this intervention and not have enrolled previously in the present study.

Exclusion criteria

-

Treatment and study plan

Peer Mentoring Intervention

Behavioral

Primary outcomes

  1. - unprotected vaginal/anal sex with HIV-negative or unknown serostatus partners in the past 3 months

  2. - lending needle or sharing cotton, cooker, or rinse water with HIV-negative or unknown serostatus partners in the past 3 months

  3. -health care visits for HIV primary care in the past 6 months

  4. -90% or more adherence to HIV medication yesterday and in the past week

Secondary outcomes

  1. -Proportion of HIV status disclosure to sex partners

Sponsors and collaborators

Lead sponsor

Centers for Disease Control and Prevention

Fed

Collaborators

  • Health Services Resource Adminstration - HIV/AIDS Bureau

Registry information

Official study title

Intervention for Seropositive Injection Drug Users - Research and Evaluation (INSPIRE)

Important dates

Study start
2001
Primary completion
2006
Study completion
2006
First posted
Sep 7, 2005
Registry last updated
Sep 27, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.